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Coronavirus disease 2019 (COVID-19) is a rapidly evolving, highly transmissible, and
potentially lethal pandemic caused by a novel coronavirus, severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). As of June 11 2020, more than 7,000,000
COVID-19 cases have been reported worldwide, and more than 400,000 patients
have died, affecting at least 188 countries. While literature on the disease is
rapidly accumulating, an integrated, multinational perspective on clinical manifestations,
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immunological effects, diagnosis, prevention, and treatment of COVID-19 can be of
global benefit. We aimed to synthesize the most relevant literature and experiences
in different parts of the world through our global consortium of experts to provide a
consensus-based document at this early stage of the pandemic.
Keywords: COVID-19, coronavirus, intensive care management, prevention, workplace safety, infection control,
SARS-CoV-2, physical distancing
INTRODUCTION
In December 2019, a cluster of pneumonia cases of an unknown
cause was reported in Wuhan city, the capital of Hubei province
in China (1). The novel coronavirus, subsequently named severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was
identified via deep sequencing of patients’ respiratory tract
samples (2); the disease was designated in February 2020 by the
World Health Organization (WHO) as coronavirus disease 2019
(COVID-19) (3). The original cluster of cases was linked to a
seafood market with presumed zoonotic transmission, followed
by efficient person-to-person transmission (4). Since the initial
reports, COVID-19 has rapidly spread fromWuhan to the rest of
the world with cases and fatalities increasing rapidly. The WHO
declared COVID-19 as a pandemic on March 11 2020.
CoVs are large enveloped non-segmented positive-sense
single-stranded RNA viruses, and COVID-19 is the third known
zoonotic coronavirus disease after severe acute respiratory
syndrome (SARS) and the Middle East respiratory syndrome
(MERS) (5). While all three of these known zoonotic CoV
belong to the β-coronavirus genera (6), SARS-CoV-2 is a
distinct new β-coronavirus belonging to the subgenus botulinum
of Coronaviridae (2). As COVID-19 is a new and rapidly
evolving pandemic, knowledge on the disease pathogenesis,
clinical manifestations and diagnosis, optimal treatment, and
preventative strategies are evolving. Our goal was to rapidly
synthesize the accumulating data through our global consortium
of experts and to provide an overall overview on COVID-
19 disease.
SARS-CoV-2 CHARACTERISTICS, VIRAL
SHEDDING, AND DIAGNOSTIC TESTING
SARS-CoV-2 has more than 80% homology to SARS-CoV and
50% to MERS-CoV (7). Although the pathogenesis is not yet
precisely defined, the virus enters human cells through the
ACE2 receptor (8, 9). Replicating strains have evolved, as many
mutations and deletions in coding and non-coding regions of
SARS-CoV-2 have been detected (10). There is variation in
SARS-CoV-2 detection in body compartments (Figure 1) (11–
15). Consistent with other human CoV (hCoV) (16), SARS-
CoV-2 has been shown to be shed by asymptomatic subjects to
a yet unknown extent (17–19), and it has been suggested that
infectiousness might peak on or before symptom onset (20).
SARS-CoV-2 can remain viable in aerosols and on surfaces.
In studies of experimentally induced aerosols SARS-CoV2 was
detected for at least 3 h in aerosols in one study (21) and for
16 h in another study (22), which also detected viable virus.
SARS-CoV-2 was still detected after 72 and 48 h on plastic
and stainless steel, respectively. On copper and cardboard, no
viable virus was apparent after 4 and 8 h, respectively (21).
In addition to droplet transmission, outbreaks of SARS-CoV-2
that are related to indoor crowded spaces have also suggested
aerosol transmission (23–25). The recent WHO statement on the
transmission of SARS-CoV-2 still concludes that transmission
occurs mainly through direct, indirect, or close contact with
infected persons through infected secretions (saliva, respiratory
secretions, or respiratory droplets) (26).
Nucleic acid amplification tests (NAAT) of SARS-CoV-2 are
currently the gold standard for COVID-19 laboratory diagnosis
(27). Limitations in testing include the availability of tests, the
need for appropriate swabbing, reduced sensitivity later in the
course of the disease (14, 28, 29), and a lag time between
obtaining testing and receiving the results, leading to a delay
in patient-related actions. The use of oropharyngeal saliva with
good sampling have matched the sensitivity of a nasopharyngeal
swab in the diagnosis of COVID-19, and yet are able to reduce
the workload and protective equipment consumption of health
care workers (28). Rapid tests reduce this lag time allowing for
more immediate detection (30) and are based on isothermal
RNA amplification (31), detection of SARS-CoV-2 antigen in
the nasopharynx, and detection of antibodies in blood (32).
Two rapid NAATs, developed by Luminex and Abbott, providing
results in < 1 h have been licensed (32). Rapid antigen detection
tests would be a suitable alternative when PCR is not readily
available, and it has the advantage of low-cost and short time to
results (29, 33) [e.g., Sona Nanotech (Halifax, Canada)].
Anti-SARS-CoV-2 antibodies (IgM/IgG) appear 4–5 days
after infection (34, 35), and the seropositivity rate is 50 and 100%
after 7, and 14 days of infection, respectively (14). Serology can
thus confirm infection in cases that are negative by PCR/antigen
detection in patients presenting after 2 weeks from symptoms
onset, and in symptomatic contacts of a confirmed case, where
contact happened more than 7 days before testing (28).
IMMUNE RESPONSE TO SARS-CoV-2
The innate immune system provides the first line of defense
against viral attacks. However, evidence emerging from in vitro,
ex vivo, and in vivo animal models and human studies suggest
that SARS-CoV-2 drives an inappropriate innate inflammatory
response characterized by low levels of IFN I and III interferon
alongside high-inflammatory cytokines, particularly IL-1RA, and
IL-6 (36, 37). COVID-19 patients with mild-moderate disease
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FIGURE 1 | Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by polymerase chain reaction after illness onset. Based on *11, §12, ‡13,
#14, ¶15. The figure was created with Biorender.com.
experience a low-grade innate response (38), while those with
severe disease have high plasma levels of pro-inflammatory
cytokines and chemokines such as IL-2, IL6, IL-7, TNF-α, G-CSF,
MCP-1, MIP-1α, and IP-10 (39–41). Furthermore, upregulated
chemoattractant chemokines cause the local trafficking of
multiple inflammatory cells, including macrophages, natural
killer (NK) cells, neutrophils, and T cells, all of which contribute
to immunopathology (36). This also accounts for the well-
described association between high neutrophil count and disease
severity (42).
Neutralizing antibodies (nAbs) against SARS-CoV-2 are
thought to be a key component of adaptive protective
immunity, yet many patients who recover from COVID-19 only
develop low levels of nAbs, while those with severe disease
experience an early rise, suggesting a more nuanced role for
nAbs, and a possible contribution to immunopathology (43).
In addition to neutralization, antibody-induced complement
mediated cytotoxicity is also thought to contribute to COVID-19
disease severity (43). Antibodies to both SARS-CoV and MERS-
CoVwane with time, it will be important to knowwhether SARS-
CoV-2 antibodies confer long-lasting immunity and protection.
Infection with hCoVs other than SARS-CoV andMERS-CoV are
common and also induce coronavirus-specific antibodies, some
of which are cross-reactive with SARS-CoV-2 but of different
functional quality (44). Poor or non-nAbs antibodies may drive
the antibody dependent enhancement (ADE) of disease, leading
to greater disease severity on subsequent contact with the virus
(45). This could hinder the development of safe and effective
SARS-CoV-2-specific vaccines (46), however, ADE has not yet
been described in patients suffering from COVID-19 (43).
CD4+ and CD8+ T cells are important in controlling viral
infections, including SARS-CoV and MERS-CoV (47–50). Our
understanding of the role of T-cell mediated immunity (CMI)
in COVID-19 is only just being teased out, but a number
of studies report virus-specific CD4+ and CD8+ T cells in
COVID-19 individuals, particularly CD8+ T cells. These cells
are mostly of an activated, and in some reports more exhausted,
phenotype (51). It has been suggested that dysregulated T cell
function may contribute to the immunopathology observed in
COVID-19. While those with mild-moderate disease maintain
their lymphocyte counts and have more polyfunctional T cells,
studies variously report lower or higher cytotoxicity of CD8+
T cells in those with severe disease (51). The lymphopenia that
accompanies severe SARS-CoV-2 infection (52, 53)might suggest
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viral-induced suppression of CMI, although this could also be




Several reports of COVID-19 in children have been published
(13, 54–59). Children aged <18 years compromised 1 and 1.7%
of US (60) and Italian COVID-19 cases (61). In a review of
171 children with COVID-19 from China, fever was present
in 41.5% (54), nearly 16% were asymptomatic, and 7% had
radiologic features of pneumonia with no symptoms. Although
three patients required invasive mechanical ventilation, all had
coexisting medical conditions and all patients recovered. In
another study from China of 2,135 children with COVID-19
(34% laboratory-confirmed, 66% had suspected disease), 90%
were asymptomatic or had mild-moderate disease (59), and one
child died. Other smaller case series reported that most children
with COVID-19 presented with fever, cough, sore throat, and
a small percentage had vomiting and diarrhea (13, 55–58). The
virus may persist in the stool of children but whether this is
transmissible has not been shown (62). Data on 2,527 pediatric
patients reported to the US CDC showed that 73% of 293
children (with data on symptoms) had fever, cough, or shortness
of breath. Of 745 children in the US series with information
on hospitalization, 147 (20%) were hospitalized and 15 (2%)
were admitted to the ICU. Of 345 patients with information
on comorbidities, 80 (23%) had at least one comorbidity with
chronic lung, and cardiovascular disease most common. Three
patients died (60).
Recent data from one New York City pediatric hospital
revealed that 16/50 (32%) of those admitted required mechanical
ventilation, comorbidity was found in 33/50 (66%), and that the
most common comorbidity was obesity reported in 11/50 (22%)
patients (63). Only one fatality was reported from sudden cardiac
arrest that followed a period of severe hypoxemia. In this cohort,
infants, and immune-compromised children did not suffer from
severe disease, but the numbers were small (63). Another study
on hospitalized children admitted to a tertiary care center in
New York City revealed that 14/46 (30.4%) were obese, but this
comorbidity was not associated with admission to the PICU, and
one patient died (CFR of 2%) (64). A recent study of 46 Canadian
and US pediatric intensive care units reported on 48 patients
admitted during a 3-week period. Notably, only 35% of the 46
hospitals reported admissions of children with COVID-19 to the
PICU, which further emphasizes that severe disease is relatively
less frequent in children. In this small cohort, comorbidity was
noted in 40/48 (83%), 18/48 (38%) required invasive ventilation,
and the overall CFR was 4.2% (65).
A newly described inflammatory disease related to SARS-
CoV-2 has recently been reported in children. It has been
termed Pediatric Multisystem Inflammatory Syndrome (PMIS)
or Multisystem Inflammatory Syndrome in Children (MIS-
C). Reports from Europe and the U.S. describe critically ill
children with fever, rash, conjunctivitis, abdominal complaints,
shock, and significant cardiac dysfunction (66–71). Several of
the children described appeared to have had a history of prior
SARS-CoV-2 infection several weeks earlier or have anti-SARS-
CoV-2 antibodies detected. Case definitions have been developed
to better characterize these patients (72). Empiric treatment
has generally involved high-dose intravenous immunoglobulin
(2 g/kg), steroids, and rarely more targeted anti-inflammatory
medications such as anakinra (68–71).
Pregnancy
Small case series described the clinical features in pregnant
women with COVID-19 (73–75). Signs and symptoms in
pregnant women were similar to non-pregnant individuals (76).
Chen et al. (73) reported that all 9 women in their report
with COVID-19 had cesarean sections, 2 for fetal distress, 2
for preterm premature rupture of the membranes, and one for
preeclampsia. Overall, premature delivery is reported in 47%
(15/32) of COVID-19 cases in pregnancy (77). Recently, a 2nd
trimester miscarriage in a pregnant woman with COVID-19 was
reported, with SARS-CoV-2 detected by PCR in the placenta (78).
Vertical transmission of SARS-CoV-2 to the infant is a
potential concern (79–81). Some reports have not documented
vertical transmission of SARS-CoV-2 (73–75, 82), others have
described potential transmission (83). A report of 10 sick
neonates born to women with COVID-19 had fetal distress,
premature labor, respiratory symptoms, and one died, but vertical
transmissionwas not documented (82). Small case series reported
on the presence of anti-SARS-CoV-2 IgM at birth or early life
in asymptomatic newborns of women with COVID-19 (84, 85).
The presence of IgM in newborns suggests that it is of fetal
origin. Out of 33 newborns of women infected with SARS-CoV-2
during pregnancy, three had early-onset SARS-CoV-2 infection,
but their outcome was favorable and it is unclear whether they
were infected in-utero or after birth (86, 87). Overall, growing
evidence suggests that vertical transmission is not to be expected
(88, 89).
The UK Royal College of Obstetricians and Gynecologists
most recent statement published April 17 2020 recommends
that antenatal care to be continued routinely, and attention
for the hypercoagulable state of a pregnant woman in view of
COVID-19 hypercoagulability, has to be considered, as well as
the mental health of pregnant women (90). Although it was
suggested that neonates should be isolated when infected (91), the
WHO and several national bodies recommend isolation together
with the mother. SARS-CoV-2 has not been detected in human
milk and thus breast-feeding should be encouraged, although all
the measures required to avoid transmission from the mother
are needed.
Adults
Early in the disease course, adults infected with SARS-CoV-
2 may present with fever, alterations in taste and/or smell
and mild respiratory or gastrointestinal symptoms (12, 92,
93). Later during disease, a fraction of patients may develop
shortness of breath, chest tightness, and palpitations leading to
hospitalization (94). Cohorts may differ for age and presence of
comorbidities [mainly hypertension, diabetes mellitus, chronic
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obstructive pulmonary disease [COPD], coronary heart disease,
cerebrovascular disease, and malignancy] leading to variable
outcomes. In fact, while a cohort of 1,099 adults with COVID-19
fromChina, themedian age was 47 years and 25% had underlying
chronic illness, a cohort of 5,700 patients (median age 63 years)
from New York (USA) presented a chronic comorbidity in more
than 60% and an Italian one with 1,591 patients (median age 63
years) presented at least one comorbidity in 68% (94–96). While
80% of patients of the Chinese cohort hadmild disease, 15.7% had
severe disease, the majority of these patients were older than 65
years and those with coexisting morbidities, and 5% were critical,
requiring ventilatory or extracorporeal membrane oxygenation
(ECMO) support. Another study from China concentrated on a
more severe cohort of patients, of whom 54 out of 191 died (12).
Nearly half of the patients had underlying comorbidities (30%
of the entire cohort had hypertension and 19% had diabetes).
Death was associated with older age, higher disease severity
score (SOFA), and elevated blood d-dimer on admission. These
findings may help to identify patients who will go on to have
severe disease. Using data from 169 hospitals in Asia, Europe,
and North America, independent risk factors for death were
age > 65 years, coronary artery disease, heart failure, cardiac
arrhythmia, and COPD (97), a finding that is supported by
a recent multicenter US study (98). It has been reported that
the prevalence of asthma in patients with COVID-19 is lower
than in the geography-matched adults population, and it has
been suggested that respiratory allergies might be associated with
reduced ACE2 expression in airway cells (41, 99). Initial data
suggested that gender has also been shown to differentially affect
the outcome of COVID-19 patients. A small study from China
found that men with COVID-19 are more at risk for worse
outcomes and death, independent of their age (100), a finding
later confirmed by an interim meta-analysis (101).
Recently, it was reported that 12/38 adult patients with
COVID-19 had ocular manifestations (e.g., conjunctival
hyperemia, chemosis, epiphora, or increased secretions) (102).
Guillian-Barre syndrome was also associated with SARS-CoV-
2 infection in 5 out of 1,000–1,200 admitted patients in 3
hospitals in Italy after an interval of 5–10 days after illness
onset (103). However, the causal relationship remains to be
investigated. Large vessel stroke has also been reported to be
a presenting symptom of COVID-19 in a small case series in
young adults (104).
Elderly
COVID-19 is severe in older individuals. Death rates have been
reported as higher in Italy, Spain, and France in comparison to
China, perhaps related to older populations in Europe. These
countries differ in the percentages of population over 65 (the
age-group most afflicted by infection, 23% in Italy) and life
expectancy (e.g., 83.4 years in Italy vs. 76.7 years in China)
(105). These demographic differences could partially explain why
Italy has a higher overall case-fatality rate CFR (7.2%) compared
with China (2.3%). Interestingly, the CFR in Italy and China
are similar for age groups 0–69 years, but higher in Italy among
>80 years old patients (52% of deaths, 20% CFR), and especially
>90 years old (22.7% CFR) (105). However, CFR should be
interpreted with caution as it is affected by testing strategy and
capacity and the number tested.
Aging is accompanied by immune senescence and the
enhanced tendency to inflammation (106). The chronic increase
in inflammatory cytokines may explain the higher tendency for
pulmonary fibrosis and clotting dysfunction following infection
with SARS-CoV-2, especially in older patients with multiple
comorbidities (39, 107), which affect >60% of people >65
years of age (108). Data from 355/2003 (17.7%) Italian patients
who died from COVID-19 showed that nearly 50% had ≥3
comorbidities (105). Cardio-respiratory and metabolic diseases
were associated with poor prognosis (39). The use of multiple
medications and the potential drug-drug interaction might
increase the risk of adverse drug effects and thus require a
careful evaluation.
Comorbidities, anti-viral and concomitant medication, and
COVID-19 appear to be associated with hyperactive delirium,
especially in hospitalized patients with pre-existing cognitive
impairment (109). As suggested by NICE rapid guidelines and
the Canadian Frailty Network, the assessment of all adults for
frailty is highly recommended especially at hospital admission,
which can guide clinicians in the decision to admit to ICU
and in selecting therapeutic choices (110). A grading system
has also been reported for US hospitals to provide a framework
for making allocation decisions (111). However, the European
Geriatric Medicine Society has stated that advanced age should
not be a criterion for excluding patients from care (112).
RADIOGRAPHIC FEATURES
Although the diagnosis of COVID-19 is based on the
identification of SARS-CoV-2 by PCR, radiological findings
are useful complements in the diagnosis and management of
COVID-19 pneumonia. However, there is still no consensus for
the use of chest radiography or computed tomography (CT) for
evaluating patients with suspected COVID-19 pneumonia. The
British Society of Thoracic Imaging considers chest radiography
as a key decision tool for suspected COVID-19 pneumonia (113).
As the predominant pattern seen in COVID-19 pneumonia is
ground-glass opacification, detecting COVID-19 pneumonia on
chest radiography is likely to be challenging, and is complicated
by the presence of comorbidities. The Chinese experience
indicates that chest CT is the preferred diagnostic modality for
COVID-19 pneumonia (114). The most common CT findings
of the COVID-19 pneumonia, ground glass opacification and/or
consolidation, mainly reflect diffuse alveolar damage and/or
organizing pneumonia, which overlap with non-COVID-19
etiologies (Figure 2) (114). Specificity for COVID-19 pneumonia
can be increased if its peripheral distribution, fine reticular
opacity, and vascular thickening is included (115). There is a
correlation between the severity of pulmonary findings on CT
and patients outcome (116). Thus, even if not specific, it has been
suggested that chest CT could be used as a helpful diagnostic
test in the emergency work up of COVID-19, complementing
PCR. Chest CT had higher sensitivity for early diagnosis of
COVID-19 compared with PCR (117), however, it should be
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FIGURE 2 | Representative computed tomography (CT) images of various manifestations of the COVID-19. (A) Coronal chest CT images show patchy ground-glass
opacities involving both lungs. (B) Ground glass may also appear widespread, confluent, and peripherally distributed. (C) Consolidation and rounded nodules may be
also observed in association with ground glass opacities.
reserved for patients who are not improving or who show
worsening respiratory symptoms. It should be noted that 11–15%
(sporadically up to ∼50%) of patients may have normal chest
CT scans up to 2 days after the onset of symptoms (118). The
latter findings and the necessary cleaning procedures of both the
CT room and personal protection equipment may challenge its




Pharmacological treatment includes drugs targeting key
components of the virus entry to alveolar epithelial cells or
their reproduction or the host immune system (Figures 3, 4).
Lopinavir/ritonavir evaluated in an open label randomized
controlled trial in severe cases and late-presenters (median
13 days from symptoms onset), failed to show significant
improvement in virologic or clinical response compared to
standard of care (140). Gastrointestinal adverse effects including
nausea and diarrhea, and drug-drug interaction limit its use in
older patients with polypharmacy.
Studies have suggested that the SARS-CoV-2 induces low
levels of IFN I and III (36, 37). Recently, a phase-2 open label
randomized controlled trial showed that early treatment (median
of 4 days from symptoms onset) with the triple combination
of interferon beta-1b, lopinavir-ritonavir, and ribavirin was safe
and highly effective in shortening the duration of viral shedding,
alleviating symptoms, and reducing cytokine responses, when
compared to lopinavir-ritonavir alone in mild to moderate
cases (141).
Chloroquine and its alternative hydroxychloroquine showed
in vitro activity (142). However, available clinical data failed to
show a clinical benefit of hydroxychloroquine either as treatment
or prophylaxis (143–145) which was confirmed in a recent meta-
analysis (146). Cardiotoxicity (e.g., prolongation of QT leading
to torsades de pointes) is a well-known adverse effect of these
drugs and should be balanced (147–150). Promising results of
a recent phase 2 study exploring the efficacy of a combination
of interferon beta-ib, lopinavir-ritonavir, and ribavirin warrant
further evaluation (141).
Remdesivir is a broad-spectrum antiviral with potent activity
against RNA viruses (151, 152). It reduced viral loads in SARS-
CoV-infected mice (151) and has potent in vitro activity against
SARS-CoV-2 (53). A 10-day course has been shown to be
associated with clinical improvement in 36 out of 53 COVID-
19 patients (153), but the lack of control group challenges
the interpretation of such data. In a recently published RCT,
Remdesivir use was not associated with a statistically significant
difference in time to clinical improvement compared with
placebo among patients with symptom duration of 12 days or
less. However, the study was stopped before reaching the pre-
specified sample size challenging any definite conclusions (154).
A phase 3 study did not show a difference between a 5-day
course and a 10-day course but unfortunately lacked a placebo
arm to determine its benefit compared to standard of care (155).
However, when compared to placebo it was able to show a
shortening of time to recovery (156). Tolerability is expected to
be good based on its high viral selectivity. Remdesivir has been
issued emergency use authorization by the FDA and is being
evaluated by the EMA for a conditional marketing authorization.
Interleukin receptor inhibitors like tocilizumab and anakinra
have been suggested to curb the cytokine storm (157–159).
Drugs like ribavirin, favipiravir, umifenovir, nitazoxanide,
darunavir/cobicistat, and IFN-beta are being investigated
(157, 160).
The use COVID-19 pharmacological therapies is
recommended in the context of clinical trials (143). When
designing drug trials it is important to use physiologically-
based pharmacokinetic (PBPK) models to select the most
appropriate dose likely to be successful (142). Drugs
eligible for further evaluation against COVID-19 drug lung
concentrations should at least exceed in vitro EC90 values
(161). In addition, the timing of drug administration is another
important consideration. WHO is leading a multi-country,
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FIGURE 3 | Drugs under investigation for potential use for Coronavirus disease-19 targeting SARS-CoV-2 and their proposed mechanism of action. Umifenovir inhibits
the fusion of the virus to the cell (119, 120). Camostat mesylate inhibits the cellular serine protease TMPRSS2, which has been suggested to be a potential entry of the
virus (8, 119). Chloroquine (CQ)/hydrochloroquine (HCQ) mechanism of action is still unclear, however it has been suggested that the drug inhibits the glycosylation of
ACE2, and disrupts the late stages of viral entry (119, 121–123). Baricitinib is suggested to have an effect on the endocytosis due to the inhibition of AP-2-associated
protein kinase 1 (119, 124). Lopinavir/ritonavir and ASC-09/ritonavir are protease inhibitors, lopinavir/ritonavir is inhibiting the 3CLpro proteinase, which is translating
the polypeptide from the genomic RNA (125). Remdesivir is an adenosine analog that moves into the viral RNA and inhibits the RNA-dependent RNA polymerase,
which stops the RNA synthesis (119, 126). Baloxavir marboxil, in the influenza virus, inhibits the protein cap-dependent endonuclease, which results in inhibiting viral
transcription (127). Azvudine is a nucleoside reverse transcriptase inhibitor that potentially affects the replication of SARS-CoV-2 (128). A proposed mechanism of
action for favipiravir is the inhibition of the viral RNA synthesis due to its wide anti-RNA virus activity, it is known to also inhibit the RNA-dependent RNA polymerase
(129, 130). Ribavirin has a broad antiviral activity, it is suggested to have an indirect effect on the RNA replication (131). The figure was created with Biorender.com.
randomized trial comparing standard of care with remdesevir,
lopinavir/ritonavir, lopinavir/ritonavir, and IFN-beta1a, or
chloroquine/hydroxychloroquine (solidarity trial).
Intensive Care Management
The COVID-19 pandemic is having a highly significant impact
on ICUs (162). Early data from China (163) reported that 5%
of all COVID-19 patients required ICU admission and the CFR
of patients with ARDS was 54% (164). Patients admitted to the
ICUs with ARDS present with a severe form of the disease and
require mechanical ventilation and 5% required ECMO. Data
from Italy on 1,591 patients admitted to the ICU in the Lombardy
region showed that of 1,403 patients with available data on
comorbidity, 709 (68%) had at least one comorbidity and 509
(49%) had hypertension. Patients older than 64 years old had a
higher mortality rate than patients younger than 63 years old, 36
vs. 15%, respectively (96).
The Surviving Sepsis Campaign recommendations provide
guidance on the management of adults with COVID-19 in
the ICU and these guidelines grade the evidence and provide
best practice statements where evidence is lacking (165),
such as: the use of fit-tested FFP2 respirators for personal
protection of healthcare workers, the use of negative pressure
rooms for patients having aerosol generating procedures, and
the performance of endotracheal intubation by experienced
personnel to avoid nosocomial spread of SARS-CoV-2. Areas
where no recommendation was made include the use of helmet
non-invasive ventilation or the therapeutic use of antivirals,
chloroquine or hydroxychloroquine, interferon gamma,
anakinra, and tocilizumab. One important area of controversy is
the use of corticosteroids for ARDS. Although steroids have been
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FIGURE 4 | Host targeted drugs with potential use for Coronavirus disease-19 and their proposed mechanism of action. (A) Anakinra, is a human Interleukin 1
receptor antagonist, and tocilizumab is a monoclonal antibody that binds to IL-6 receptors (132, 133); (B) Azithromycin inhibits phosphorylation of S6RP in the mTOR
pathway in T cells, which leads to reduced cell growth, protein synthesis, and increased apoptosis and autophagy of T cells (134); (C) Immunomodulating effects of
chloroquine and hydroxychloroquine, which inhibits the production of IL-1, IL-1β, IL-6, and TNFα (121, 135, 136); (D) Baricitinib inhibits the activation of different
interleukins and growth factors through inhibiting the JAK1 and JAK2 on the cytokine receptor (137–139). The figure was created with Biorender.com.
recommended for patients with ARDS (165), their use should
be individualized and is preferable in settings with clinical trial
capacity (143, 166). ARDSNet guidelines recommend against the
routine use of corticosteroids in patients with ARDS. However,
the recent SSC COVID-19 guidelines recommend their use
in COVID-19 patients with ARDS (weak evidence) although
without full agreement from all panel members. Guidance for the




The initial WHO case definitions for COVID-19 consider
suspected, probable, and confirmed cases and requests national
authorities to report both probable and confirmed cases
(Panel 2). Case-based reporting is done daily, and aggregated
data are sent to the WHO on a weekly basis. Selected health
conditions, which may predispose people to COVID-19 (e.g.,
pregnancy, cardiovascular diseases, and immunodeficiency) are
reported, and whether the patient is a health care worker.
The case definitions are established to verify that individuals
with the highest risk of acquiring the disease are tested. This
helps in providing early isolation and avoids further transmission
of SARS-CoV-2. History of exposure is reported to document
transmission patterns in the communities and 14 days is
considered as the incubation period to cover a relatively large
confidence interval (168). Therefore, history of travel in the last
14 days and the list of country/countries where the individual is
traveling from are also reported. Once community transmission
has been documented, case definitions require modification and
should be based on the most common symptoms. It was recently
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PANEL 1 | Recommended management of patients admitted to intensive care
unit with Coronavirus disease-19.
• Indication for admission is severe respiratory failure due to pneumonia and
acute respiratory distress syndrome with or without shock.
• If the patient is not intubated, perform a trial with non-invasive mechanical
ventilation* (preferred option) or high-flow nasal cannula (alternative option, if
non-invasive mechanical ventilation is not available) (4–6 h). HFN is preferred
due to its better tolerance.
• If the patient does not respond, intubate the patient by skilled personnel with
maximal precautions.
• Obtain an endotracheal aspirate for bacterial and fungal stains and culture and
for PCR viral detection.
• Use protective mechanical ventilation according to Surviving Sepsis Campaign
(SSC) recommendations.
• Use prone position if the patient has a PaO2/FiO2 ratio equal or lower than 100
(12 h minimum).
• Consider ECMO when refractory hypoxemia despite prone position.
• Manage shock according to SSC recommendations.
• In patients with ARDS administer prednisone or methyl prednisolone (SSC,
weak recommendation).
• In patients with persistent high D-dimer levels (>3,000 U/mL) consider
anticoagulation and rule out pulmonary thromboembolism.
• Do not withhold antibacterial treatment.
• Continue or change anti-COVID-19 treatment according to hospital protocols
and published evidence.
*Non-invasive mechanical ventilation with Helmet commonly used in intensive care units
in Italy.
PANEL 2 | World Health Organization Coronavirus disease-19 (COVID-19) case
definitions (as updated March 16, 2020).
Suspect case:
A patient with acute respiratory illness [fever and at least one sign/symptom of
respiratory disease (e.g., cough, shortness of breath)], AND with no other
etiology that fully explains the clinical presentation AND a history of travel to or
residence in a country/area or territory reporting local transmission of COVID-19
disease during the 14 days prior to symptom onset.
OR
A patient with any acute respiratory illness AND having been in contact with a
confirmed or probable COVID- 19 case in the last 14 days prior to onset of
symptoms.
OR
A patient with severe acute respiratory infection (fever and at least one
sign/symptom of respiratory disease (e.g., cough, shortness breath)) AND
requiring hospitalization AND with no other etiology that fully explains the clinical
presentation.
Probable case
A suspect case for whom testing for COVID-19 is inconclusive (as reported by
the laboratory).
Confirmed case
A person with laboratory confirmation of COVID-19 infection, irrespective of
clinical signs, and symptoms.
Based on World Health Organization case definition (as updated March 16, 2020) (167).
shown that the prevalence of SARS-CoV-2 among patients that
would have missed risk-based testing was ∼5% among adults
with flu-like symptoms in California (169).
PANEL 3 | Infection control and containment measures considerations specific for
SARS-CoV-2 infection.
• The capacity of SARS-CoV-2 to survive up to several hours on surfaces
requires careful disinfection measures and additional hygiene precautions
(e.g., wearing gloves for exposed individuals, washing hands frequently,
preventing contact of hands with mouth, and eyes) (179).
• The specific features of SARS-CoV-2, which spreads very rapidly with a short
incubation time as to infect exponentially thousands of individuals in all age
groups (162), calls for the implementation of specific containment measures.
• The containment approach is usually based on case isolation and quarantine
(which includes contacts) in early stages, with contact tracing of infected
individuals. More stringent measures to limit the speed of the infection curve
and to ensure a more diluted pressure on health services include social
distancing (e.g., keeping at least one meter between individuals), limitations of
internal movement and reduction of social activities, including a “stay home”
approach (e.g., home-work encouraged, movement allowed for essential
services/medical needs/food purchasing), closure of schools, bar, restaurants,
cinemas, and similar activities, and in some cases closure of borders and
creation of isolated “red zones” (179, 180).
• Prompt and adequate communication to the general public and training of
health care workers are essential components of the COVID-19 response.
Infection Control
Traditionally, infection prevention and control principles are
based on a hierarchy of administrative, environmental, and
personal protective measures (masks for infectious patients and
respirators for airborne agents to protect health care workers
and visitors) (170). This approach has been well-summarized for
tuberculosis (170), but has also been suggested for COVID-19
(171, 172). While N95/N99/FFP2/FFP3 masks are recommended
to protect health care workers and other exposed individuals in
the workplace, there is debate on the use of surgical masks (173,
174). Although there is agreement on the use of surgical masks to
limit the spread of droplet nuclei for symptomatic patients under
isolation, there is an ongoing dialogue for the potential mass
use of surgical masks to limit the community spread of COVID-
19 in early stages infection and from asymptomatic individuals
(171–175). Arguments against this have been raised, based on
the potential false sense of protection this can generate and
the potential risks of moisture retention, long mask re-use, and
limited filtration capacity (176). Studies performed on influenza
confirm that surgical masks are up to 3 times more effective
in reducing droplet transmission than home-made masks (176,
177). The interim WHO guidance (5 June 2020) on the use of
masks in the context of COVID-19 states that the use of masks
by healthy people in the community is not supported by high
quality evidence. However, governments should encourage the
general public to wear masks in specific situations and settings
(178). Specific infection control considerations for COVID-19
are detailed in Panel 3.
Country-Specific Responses
On March 18 2020, the WHO Regional Office for Europe
issued a statement (181) summarizing the situation of Europe
as under the “Four Cs” scenarios of the outbreak: (1) no
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case; (2) first case; (3) first cluster; and (4) first evidence
of community transmission. The pandemic is progressing at
different speeds and at different times in different countries,
depending on demographics and other factors (e.g., population
mixing, migration, and international travel). However, the basic
actions to be undertaken under each scenario are the same.
These include strict measures to interrupt human-to-human
transmission including active case-finding followed by rapid
diagnosis and isolation with immediate physical distancing
and travel-related (e.g., travel restrictions and border closure)
measures (182, 183).
Surveillance is critical in understanding the progression of
the pandemic. Rapidly establishing sensitive surveillance and
widespread testing ensures that cases are identified promptly and
effective contact tracing is in place in the early stages when there
are only a small number of cases. As the outbreak progresses,
seroprevalence studies can help in estimating infections in
communities, the extent of spread of asymptomatic transmission,
the role different age groups might be playing in enhancing
transmission, and the acquisition of population immunity.
The WHO recommended that countries: (1) prepare and be
ready; (2) detect, protect, and treat; (3) reduce transmission;
and (4) innovate and learn, while protecting vulnerable people.
Herein, we describe public health responses and lessons learned
from several countries identified because of the caseload,
the strategic importance, and direct experience within the
writing committee.
China
After the major outbreak was recognized, the city of Wuhan
was cordoned off on January 23 2020 (184). However, around 5
million people had already left Wuhan during the peak transport
period before the Chinese New Year. An extreme form of social
distancing and compulsory mask-wearing in public places were
undertaken all over the country to block human-to-human
transmission (173, 185). These measures appeared to eliminate
most of the transmissions with unclear links in the community,
and many of the subsequently observed cases then appeared in
clusters, mostly involving families (76). Intensive case-finding
and isolation were undertaken together with contact tracing and
quarantine of contacts and other high-risk groups using big data
and artificial intelligence. The spread of COVID-19 was rapidly
brought under control outside the province of Hubei, allowing
for the staged resumption of essential economic activities with
modification of the work process and environment to minimize
person-to-person contact.
More than 1,800 health care workers were infected in Hubei,
mostly occurring early in the overwhelmed hospitals with severe
shortages of personal protective equipment in Wuhan (76).
Successful confinement of massive outbreaks of COVID-19
to Wuhan and other cities of Hubei allowed for the timely
channeling of disaster response capacity of the country to these
seriously affected areas. Hospital capacity was rapidly expanded
with reinforced manpower and personal protective equipment to
accommodate all patients with severe disease. New intermediate
care facilities were rapidly constructed and manned by rescue
teams from other parts of the country to care for the much
larger number of patients with milder disease. Effective triage of
patients according to their treatment needs maximized the health
care capacity and throughput to accommodate all subsequent
patients in an environment safer for themselves, their families,
the health care staff, and the community.
Italy
The epidemic in Northern Italy took place about 4 weeks
after that in China, while other European countries followed
Italy with a delay of 7–10 days. Italy started creating a closed
“red zone” around the municipalities initially experiencing the
outbreaks. The “red zone” was then extended to entire Regions
(Lombardia, Veneto, part of Emilia Romagna) and then to the
entire country. Movement restrictions, closure of schools, and
other social aggregation sites were implemented early, although
people’s compliance was suboptimal initially. An extraordinary
effort was conducted to increase the number of ICU beds and to
procure masks, respirators, and ventilators, which, in the early
phases, were lacking. The response was coordinated by the Civil
Protection which is well-organized in Italy to ensure a rapid
response to earthquakes. The situation has improved significantly
since the end of March 2020.
Several countries followed this approach while others followed
slightly different ones (Table 1).
Other Experiences
The UK response has been based on (186) (1) contain (detect
early cases, follow-up close contacts); (2) delay (slow the spread,
lower the peak impact); (3) research; and (4) mitigate (provide
the best care for cases, support hospitals to maintain essential
services, ensure ongoing support for ill people in the community,
and minimize the impact of the disease on society, public
services, and economy). Early on it was thought that by “slowing
spread” rather than “suppression,” the peak could be pushed into
the summer when there is less pressure on the health service.
However, it became clear that this approach was not going
to be successful given the level of spread already within the
population. Thus, the government rapidly moved to a strategy
of “suppression” in line with the responses of other countries.
The study that predicted that the National Health Service would
be overwhelmed if a mitigation strategy continued was pivotal
in the change of the UK approach (187). This approach raised
discussions in the UK and beyond (188).
In Sweden, travels were discouraged but not prohibited,
schools partially closed, bars and restaurants continued to
operate. Sweden has chosen one of the most liberal approaches
seen in Europe, with many measures being of a suggestive,
recommended, or non-compulsory character. This approach
differs from that of other countries in Europe, and was associated
with a relatively high cumulative case incidence and mortality.
After 4 months from the epidemic onset, the overall mortality
rates are approaching normal levels in most of the affected
countries, following a period of a substantial excess mortality,
which was also observed in UK, Italy, Spain, and Belgium.
In the US, testing became free for all on March 16 2020
but, initially, there were limited numbers of tests available.
Movement of individuals was discouraged while domestic travel
























































Argentina All country: March
16






All country: March 19 Initial compulsory quarantine for all citizens
till June 7; some flexibility since May 24 in
less affected areas








bring kids to school,
only kids allowed of
critical professions.
Universities open




















businesses on March 26
Gradual reopening since May 15
Austria All country: March
16
Partial: March 11 All: March 16 All: March 16 All: March 16 All: March 16 Easing of lockdown as of May 1;
restaurants can reopen on May 15 and
hotels on May 29
Belgium All country: March
16
All country; March 16








All country: March 16 EU parliament in video-conference,
economic support package.
Easing of lockdown rules as of May 18
Brazil Partial: March 18
All country: March
30
Partial: March 17 Partial: March 16 Partial: March 13 All country: March
16
Partial: March 18 “Stay home” recommended but not
compulsory; Restrictions differ from state
to state; some flexibility in less affected
areas
Canada Partial: March 16 Not yet Partial: March 16 Partial: March 16 Partial: March 16 Not yet Some provinces begin to slowly relax
lockdown restrictions as of May 4




limiting travel of ill
individuals between







All country: March 20 Alternating quarantines of
communities/cities beginning March 25
National emergency declared March 18
Lockdown from May 15 in the capital and
metropolitan region
Denmark All country: March
11






All country: March 11 Gradual reopening from April 15 (some
private primary and secondary schools)
May 11 (additional primary schools, shops)
Phase 3 (from June 8): Almost all
remaining blocking restrictions in the
country will be removed




encouraged by the EU
authorities
















































































































All: March 16 All: March 16 All country: March
16
All country: March 16 Second round of voting canceled. The
second round of local elections has been
suspended, along with the government’s
reform agenda
Gradual reopening from May 11 (primary
schools and most businesses); lockdown
measures will be further eased from June
2; Paris and its surrounding region will





All country: March 16 Partial: March 13
All: March 16




“Landers” to decide when limiting closing
bars/restaurants
Gradual reopening from April 20
(commercial spaces under 800 sq meters,
car dealerships, bike shops, and book
stores); some schools gradually open from
May 4; no big groups and no meeting with
multiple people from different households
until June 5




of entry for selected
country or epidemic






All countries: March 19




















Seating < half capacity;
tables 1.5m apart; not
> 4 persons per table;
mask when not eating;
alcohol sanitizers and
temperature check for




March 28 to April 1
Closing bars and pubs:
April 3
Advice to stay home if possible and
self-initiated masking in public places: late
January
Stopping non-essential government
services and civil servants working at
home if possible: 29 Jan to 1 March and
again from 23 March
Gradual reopening from May 4
Italy Partial: February 24
All country: March 8
Partial: February 24
All country: March 8
Partial: February 24
All country: March 8
Partial: February 24
All country: March 8
Partial: February 24
All country: March 8
Partial: February 24
All country: March 8
Economic support package











































































































Mexico Partial: March 20
(with USA)






March 24 March 16 (soccer
matches)
Partial: many closed by
not mandatory at the
federal level
Body temperature check at mass
gathering/airports
March 23: maintain the healthy distance
16 March: all workers from the federal
government non-essential activities were
stopped, home work was suggested
Gradual reopening from May 18 (for
hundreds of counties) and from June 1
(the rest of the nation)
Netherlands Not yet. Belgium
closed the border
Partial: March 16, asked
not to leave the country
Since April 9, 14 days
quarantine if return from
specific countries/places







All country since March
16.
Churches with Max 30 persons (funerals).
Gradual reopening from May 11
Norway All country: March
16











Gradual reopening from April 20
(kindergartens and some health
specialists); Partial reopening of high
schools and universities, hair, massage,
and beauty salons from April 27; major
events canceled through at least June 15.
Poland All country: March
14
Partial: March 14 Partial: March 14 Partial: March 14 Partial: March 14 Partial: March 14 Gradual reopening from April 20 (parks,
forests); from May 4 (hotels, shopping
centers, and cultural institutions); from May
6 (nurseries and preschools); elections on
May 10 canceled; from May 28
(restaurants, salons, and sports facilities)
Portugal Not yet Partial: March 13 All: March 13 Partial: March 13 Partial: March 13 Not yet Gradual reopening from May 4 (medical
and dental clinics, hair salons, small
shops); from May 18 (bars, cafes,
restaurants, daycare centers, museums,
palaces, national monuments, art galleries,
and high schools for senior students)




All: March 21 Not yet Not yet Not yet Contact tracing (contacts of test positives)
Easing of restrictions from May 11
Spain All country: March
16






All country: March 16 Gradual reopening from May 4, with four
phase de-escalation measures depending
on the on-going progress across the
different regions

















Not yet Economic support package. Stay home












































































































































































































































































































































































































































































































































































































































































































































































































































































was still allowed. Massive testing was performed in the US and
strict quarantines were imposed in large cities with different
approaches from State to State (Table 1).
FUTURE PERSPECTIVES
The future pandemic course will depend on the early
implementation, massive diagnosis, and contact tracing/isolation
in addition to broad restrictions leading to significant and
prolonged physical distancing. Nevertheless, considering that
sufficient population immunity will be required to definitely
control the virus in the upcoming years (unless it were to
mutate to a less virulent, competing virus), which will require
several years of manageable levels of viral infection, introducing,
and retreating social restrictions proving most effective, can be
envisioned for the near future (187). Fast track drug development
and repurposing of available drugs should be informed initially
by in vitro data to support activity, PBPK data to inform dose
selection, and well-designed, prospective randomized-controlled
trials powered to detect a clinically meaningful outcome.
Safe and effective vaccines would be the most suitable
solution generating the required population immunity to stop
virus circulation. Vaccine development is in progress, both by
pharmaceutical companies and research institutions. On the
website of the WHO, a draft landscape of a growing number of
COVID-19 candidate vaccines can be found. Most vaccines are
still in the preclinical phases of the development, but some of
them are already in Phase I clinical trials (189, 190). Previous
preclinical studies with vaccine candidates for SARS and MERS
demonstrated the induction of neutralizing antibodies, but a
possibility for enhanced disease had been seen in some vaccinated
animals after challenge with the wild-type virus (191), and in
experimental models (191, 192). Potential vaccines will need to
be carefully studied, the duration of immunity assessed, and the
potential for enhanced vaccine disease will need to be carefully
evaluated over time. Importantly, from here on, the inevitable
threat of new emerging coronaviruses (193) will have to be
confronted earlier. China acted well, but too late, and the virus
spread in weeks to the rest of the world, which in turn also acted
too late, with few exceptions; and some countries continue to
do so. Preparing for new events will require coordinated efforts
between epidemiologists, clinical and basic science researchers,
and artificial intelligence experts; the time is now. Hot spots for
new coronavirus emergence need to be monitored continuously
to detect severe human cases very early on. In this new post
COVID-19 era, transparency and collaboration will be critical to
confront future pandemic threats.
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